Purpose: We report the case of a 33-year-old male who presented with unilateral central serous retinopathy three days after the injection of a COVID-19 vaccine.
Observations: A 33-year-old healthy Hispanic male referred to the ophthalmology service due to blurry vision and metamorphopsia in the right eye without any flashes, floaters, eye redness or pain. The patient reported that 69 hours prior to presentation he received the first dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine. He denied any past ocular history or pertinent medical history. He does not take any medicines and denies stressful factors in his life. The clinical examination and imaging tests were consistent with central serous retinopathy that resolved in three months.
Conclusions And Importance: This is the first report of an ocular complication potentially associated with a COVID-19 vaccination. Our case contributes information of a side effect potentially related to this new vaccine.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195685 | PMC |
| http://dx.doi.org/10.1016/j.ajoc.2021.101136 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Optic Nerve Head Changes in Acute Central Serous Chorioretinopathy: Implications for Glaucoma Risk.
Photodiagnosis Photodyn Ther
January 2025
Istanbul Medeniyet University, Faculty of Medicine, Department of Ophthalmology, Istanbul, Turkey. Electronic address:
Objective: Imaging techniques have demonstrated changes in the choroid and retina in acute central serous chorioretinopathy (CSCR), but the effects on the optic nerve head (ONH) remain unclear. This study investigates ONH structural changes in acute CSCR using enhanced deep imaging optic coherence tomography (EDI-OCT).
Methods: A prospective cohort study included 51 acute CSCR patients and 51 healthy controls aged 18-65 years.
Subthreshold nanosecond laser therapy for chronic central serous chorioretinopathy: A prospective study.
J Fr Ophtalmol
January 2025
Department of Ophthalmology, Saarland University Medical Center UKS, Homburg/Saar, Germany.
Purpose: To investigate the morphologic and functional outcomes of nanosecond subthreshold (ST) laser treatment for patients with chronic central serous chorioretinopathy (CSC).
Methods: In this prospective study, 44 patients were treated with the ST nanosecond laser with a follow-up period of 12 months. All target variables were measured at 1, 3, 6 and 12 months after the first laser treatment.
Reply to letter to editor: (Is Pachychoroid Serous Retinopathy a Better Name to Describe the Features of Central Serous Chorioretinopathy?).
Retina
December 2024
Retinal Disorders and Ophthalmic Genetics Division, Stein Eye Institute, University of California Los Angeles, Los Angeles, CA, United State.
Intravitreal steroid-associated central serous chorioretinopathy.
BMJ Case Rep
January 2025
Ophthalmology, JIPMER, Puducherry, India.
Central serous chorioretinopathy (CSC) is a known side effect of systemic steroid therapy. The role of intravitreal steroids in causing CSC is controversial. We present two cases of acute CSC that developed after intravitreal steroid injections.
View Article and Find Full Text PDFChoroidal Response to Intravitreal Bevacizumab Injections in Treatment-Naïve Macular Neovascularization Secondary to Chronic Central Serous Chorioretinopathy.
Biomedicines
December 2024
Tel Aviv Medical Center, Department of Ophthalmology, Tel Aviv University, Tel Aviv 6423906, Israel.
Background/objectives: To evaluate the impact of intravitreal bevacizumab (IVB) therapy on anatomical and visual outcomes in patients with macular neovascularization (MNV) secondary to chronic central serous chorioretinopathy (cCSC).
Methods: This retrospective observational study reviewed the medical records of treatment-naïve patients diagnosed with cCSC complicated by MNV and treated with IVB injections over a 5-year period. The presence of MNV was confirmed using optical coherence tomography angiography (OCTA).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!